Samsung Pharm & GemVax present pancreatic cancer immunotherapeutic drug, RIAVAX™, phase III results at ASCO 2021
- Saturday, June 5, 2021, 7:07
- Finance
- Add a comment
SEOUL, South Korea, June 5, 2021 /PRNewswire/ — Samsung Pharm Co., Ltd. announced today that the company presented the results of a phase III clinical trial of its pancreatic cancer immunotherapeutic drug candidate called ‘RIAVAX™ (GV1001)’ conducted in Korea at the 2021 American Society…
About the Author
adminasapcorp has written 41538 stories on this site.